Kanai M - Search Results

1

Prohormone convertase furin has a role in gastric cancer cell proliferation with parathyroid hormone-related peptide in a reciprocal manner.

Nakajima T, Konda Y, Kanai M, Izumi Y, Kanda N, Nanakin A, Kitazawa S, Chiba T. Nakajima T, et al. Among authors: kanai m. Dig Dis Sci. 2002 Dec;47(12):2729-37. doi: 10.1023/a:1021005221934. Dig Dis Sci. 2002. PMID: 12498293

2

Gastrin stimulates the growth of gastric pit cell precursors by inducing its own receptors.

Nakajima T, Konda Y, Izumi Y, Kanai M, Hayashi N, Chiba T, Takeuchi T. Nakajima T, et al. Among authors: kanai m. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G359-66. doi: 10.1152/ajpgi.00117.2001. Am J Physiol Gastrointest Liver Physiol. 2002. PMID: 11804858 Free article.

3

Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway.

Kanai M, Konda Y, Nakajima T, Izumi Y, Kanda N, Nanakin A, Kubohara Y, Chiba T. Kanai M, et al. Oncogene. 2003 Jan 30;22(4):548-54. doi: 10.1038/sj.onc.1206109. Oncogene. 2003. PMID: 12555068

4

STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells.

Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, Kayahara T, Fukui H, Sawada M, Chiba T. Kanda N, et al. Among authors: kanai m. Oncogene. 2004 Jun 17;23(28):4921-9. doi: 10.1038/sj.onc.1207606. Oncogene. 2004. PMID: 15077160

5

Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.

Kanai M, Matsumoto S, Nishimura T, Shimada Y, Watanabe G, Kitano T, Misawa A, Ishiguro H, Yoshikawa K, Yanagihara K, Teramukai S, Mitsumori M, Chiba T, Sakai Y, Fukushima M. Kanai M, et al. Int J Clin Oncol. 2007 Jun;12(3):224-7. doi: 10.1007/s10147-007-0666-x. Epub 2007 Jun 27. Int J Clin Oncol. 2007. PMID: 17566847

6

Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.

Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M. Matsumoto S, et al. Among authors: kanai m. Chemotherapy. 2008;54(5):395-403. doi: 10.1159/000154921. Epub 2008 Sep 9. Chemotherapy. 2008. PMID: 18781065

7

Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.

Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguro H, Yanagihara K, Chiba T, Fukushima M, Matsuda F. Kanai M, et al. Cancer Epidemiol. 2010 Apr;34(2):189-93. doi: 10.1016/j.canep.2010.02.008. Epub 2010 Mar 21. Cancer Epidemiol. 2010. PMID: 20308030 Free article.

8

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.

Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. Kanai M, et al. Cancer Chemother Pharmacol. 2011 Jul;68(1):157-64. doi: 10.1007/s00280-010-1470-2. Epub 2010 Sep 22. Cancer Chemother Pharmacol. 2011. PMID: 20859741 Free article. Clinical Trial.

9

Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.

Mori Y, Nishimura T, Kitano T, Yoshimura K, Matsumoto S, Kanai M, Hazama M, Ishiguro H, Nagayama S, Yanagihara K, Teramukai S, Chiba T, Sakai Y, Fukushima M. Mori Y, et al. Among authors: kanai m. Oncology. 2010;79(1-2):136-43. doi: 10.1159/000320613. Epub 2010 Dec 8. Oncology. 2010. PMID: 21150228

10

Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers.

Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T. Kanai M, et al. Cancer Chemother Pharmacol. 2012 Jan;69(1):65-70. doi: 10.1007/s00280-011-1673-1. Epub 2011 May 21. Cancer Chemother Pharmacol. 2012. PMID: 21603867 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,385 results

Search Page

Filters